An Australian Senate committee recommended last week that Parliament pass the Therapeutic Goods Amendment Bill (2016 Measures No. 1) that would overhaul drug and device regulations to speed access to novel therapies and reduce regulatory red tape.
PERTH, Australia – Australian cell therapy developer Mesoblast Ltd. is moving to phase III trials with its allogeneic mesenchymal precursor cell therapy to treat chronic low back pain due to intervertebral disc degeneration.
PERTH, Australia – Australian cell therapy developer Mesoblast Ltd. is moving to phase III trials with its allogeneic mesenchymal precursor cell therapy to treat chronic low back pain due to intervertebral disc degeneration.
PERTH, Australia – More patients with Pompe disease in New Zealand will now have access to Sanofi Genzyme's enzyme replacement therapy Myozyme (alglucosidase alfa), but not because the country's single payer will pay for the drug. Rather, Sanofi Genzyme, of Cambridge, Mass., part of Sanofi SA, has stepped in to provide the therapy for free to patients in New Zealand.
PERTH, Australia – Medicines Australia condemned a recent report that urged the Australian government to use international reference pricing for drugs reimbursed on the country's Pharmaceutical Benefits Scheme (PBS).
PERTH, Australia – Medicines Australia condemned a recent report that urged the Australian government to use international reference pricing for drugs reimbursed on the country's Pharmaceutical Benefits Scheme (PBS).
PERTH, Australia – More patients with Pompe disease in New Zealand will now have access to Sanofi Genzyme's enzyme replacement therapy Myozyme (alglucosidase alfa), but not because the country's single payer will pay for the drug. Rather, Sanofi Genzyme, of Cambridge, Mass., part of Sanofi SA, has stepped in to provide the therapy for free to patients in New Zealand.
